207 related articles for article (PubMed ID: 17203206)
1. Muscle creatine kinase/SV40 hybrid promoter for muscle-targeted long-term transgene expression.
Takeshita F; Takase K; Tozuka M; Saha S; Okuda K; Ishii N; Sasaki S
Int J Mol Med; 2007 Feb; 19(2):309-15. PubMed ID: 17203206
[TBL] [Abstract][Full Text] [Related]
2. Comparison of promoter region constructs for in vivo intramuscular expression.
Fabre EE; Bigey P; Orsini C; Scherman D
J Gene Med; 2006 May; 8(5):636-45. PubMed ID: 16477670
[TBL] [Abstract][Full Text] [Related]
3. Activator protein 1-mediated transcriptional regulation strategy sustains long-term expression of a xenogeneic gene product in vivo: an implication for gene therapy targeting congenital protein deficiencies.
Sasaki S; Smith JM; Takase K; Okuda K; Ishii N; Takeshita F
Int J Mol Med; 2006 Aug; 18(2):289-97. PubMed ID: 16820937
[TBL] [Abstract][Full Text] [Related]
4. Construction and analysis of compact muscle-specific promoters for AAV vectors.
Wang B; Li J; Fu FH; Chen C; Zhu X; Zhou L; Jiang X; Xiao X
Gene Ther; 2008 Nov; 15(22):1489-99. PubMed ID: 18563184
[TBL] [Abstract][Full Text] [Related]
5. High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter.
Yew NS; Przybylska M; Ziegler RJ; Liu D; Cheng SH
Mol Ther; 2001 Jul; 4(1):75-82. PubMed ID: 11472109
[TBL] [Abstract][Full Text] [Related]
6. Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D.
Rodino-Klapac LR; Lee JS; Mulligan RC; Clark KR; Mendell JR
Neurology; 2008 Jul; 71(4):240-7. PubMed ID: 18525034
[TBL] [Abstract][Full Text] [Related]
7. Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1alpha promoter.
Gill DR; Smyth SE; Goddard CA; Pringle IA; Higgins CF; Colledge WH; Hyde SC
Gene Ther; 2001 Oct; 8(20):1539-46. PubMed ID: 11704814
[TBL] [Abstract][Full Text] [Related]
8. CMV enhancer/human PDGF-beta promoter for neuron-specific transgene expression.
Liu BH; Wang X; Ma YX; Wang S
Gene Ther; 2004 Jan; 11(1):52-60. PubMed ID: 14681697
[TBL] [Abstract][Full Text] [Related]
9. Sustained, high transgene expression in liver with plasmid vectors using optimized promoter-enhancer combinations.
Magnusson T; Haase R; Schleef M; Wagner E; Ogris M
J Gene Med; 2011 Jul; 13(7-8):382-91. PubMed ID: 21721074
[TBL] [Abstract][Full Text] [Related]
10. Promoters influence the kinetics of transgene expression following adenovector gene delivery.
Chen P; Tian J; Kovesdi I; Bruder JT
J Gene Med; 2008 Feb; 10(2):123-31. PubMed ID: 18064718
[TBL] [Abstract][Full Text] [Related]
11. SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters.
Jayan GC; Cordelier P; Patel C; BouHamdan M; Johnson RP; Lisziewicz J; Pomerantz RJ; Strayer DS
Gene Ther; 2001 Jul; 8(13):1033-42. PubMed ID: 11438838
[TBL] [Abstract][Full Text] [Related]
12. Enhanced transgene expression in the mouse skeletal muscle infected by the adeno-associated viral vector with the human elongation factor 1alpha promoter and a human chromatin insulator.
Mori-Uchino M; Takeuchi T; Murakami I; Yano T; Yasugi T; Taketani Y; Nakagawa K; Kanda T
J Gene Med; 2009 Jul; 11(7):598-604. PubMed ID: 19399759
[TBL] [Abstract][Full Text] [Related]
13. Efficient muscle-specific transgene expression after adenovirus-mediated gene transfer in mice using a 1.35 kb muscle creatine kinase promoter/enhancer.
Larochelle N; Lochmüller H; Zhao J; Jani A; Hallauer P; Hastings KE; Massie B; Prescott S; Petrof BJ; Karpati G; Nalbantoglu J
Gene Ther; 1997 May; 4(5):465-72. PubMed ID: 9274724
[TBL] [Abstract][Full Text] [Related]
14. Sustained expression after nonviral ocular gene transfer using mammalian promoters.
Kachi S; Esumi N; Zack DJ; Campochiaro PA
Gene Ther; 2006 May; 13(9):798-804. PubMed ID: 16467860
[TBL] [Abstract][Full Text] [Related]
15. Muscle-specific enhancement of gene expression by incorporation of SV40 enhancer in the expression plasmid.
Li S; MacLaughlin FC; Fewell JG; Gondo M; Wang J; Nicol F; Dean DA; Smith LC
Gene Ther; 2001 Mar; 8(6):494-7. PubMed ID: 11313829
[TBL] [Abstract][Full Text] [Related]
16. Hybrid retroviral vector with MCK enhancers inserted in LTR for stable and specific expression of human factor IX in skeletal muscle.
Wang JM; Hou J; Qiu XF; Kurachi K; Xue JL
Chin Med J (Engl); 2004 Jun; 117(6):893-8. PubMed ID: 15198894
[TBL] [Abstract][Full Text] [Related]
17. Gene transfer into hepatocytes mediated by herpes simplex virus-Epstein-Barr virus hybrid amplicons.
Müller L; Saydam O; Saeki Y; Heid I; Fraefel C
J Virol Methods; 2005 Jan; 123(1):65-72. PubMed ID: 15582700
[TBL] [Abstract][Full Text] [Related]
18. Cre-loxP system as a versatile tool for conferring increased levels of tissue-specific gene expression from a weak promoter.
Nakamura S; Watanabe S; Ohtsuka M; Maehara T; Ishihara M; Yokomine T; Sato M
Mol Reprod Dev; 2008 Jun; 75(6):1085-93. PubMed ID: 18163444
[TBL] [Abstract][Full Text] [Related]
19. Increased level and duration of expression in muscle by co-expression of a transactivator using plasmid systems.
Li S; MacLaughlin FC; Fewell JG; Li Y; Mehta V; French MF; Nordstrom JL; Coleman M; Belagali NS; Schwartz RJ; Smith LC
Gene Ther; 1999 Dec; 6(12):2005-11. PubMed ID: 10637452
[TBL] [Abstract][Full Text] [Related]
20. Increased glia-specific transgene expression with glial fibrillary acidic protein promoters containing multiple enhancer elements.
de Leeuw B; Su M; ter Horst M; Iwata S; Rodijk M; Hoeben RC; Messing A; Smitt PS; Brenner M
J Neurosci Res; 2006 Apr; 83(5):744-53. PubMed ID: 16496373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
